Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD – A phase 2A clinical trial
CX717, a low-impact ampakine, is a positive allosteric modulator of AMPA-glutamate receptors. This clinical study evaluated CX717 for the treatment of ADHD symptomology in a randomized, double-blind, placebo-controlled, multi-center, 2-period…
Suggested reading